

NEWS & VIEWS REFERENCES

1. Hossain M, et al. Total chemical synthesis of a nonfibrillating human glycoinsulin. *J. Am. Chem. Soc.* Jan 2020, 142, 3, 1164-1169.
2. Murnaghan J, Talalay P. John Jacob Abel and the crystallization of insulin. *Perspectives in Biology and Medicine*, Vol 10, No. 3, pp. 340-369. Johns Hopkins University Press.
3. Muzaffar M, et al. The Mechanism of Enhanced Insulin Amyloid Fibril Formation by NaCl Is Better Explained by a Conformational Change Model. 2011 *PLOS ONE* 6(11): e27906
4. Pftzner A, et al. Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events. *J Diabetes Sci Technol.* 2015 Nov; 9(6): 1292–1298
5. Liu G et al. Smoking cessation and weight change in relation to cardiovascular disease incidence and mortality in people with type 2 diabetes: a population-based cohort study. Volume 8, Iss 2, P125-133, February 01, 2020

FEATURE REFERENCES

p 8-12 Skin Deep

1. Cho NH, Shaw JE, Karuranga S, Huang Y, Da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Research and Clinical Practice.* 2018;138:271-81.
2. Horton BW, Boler LP, Subauste RA. Diabetes Mellitus and the Skin: Recognition and Management of Cutaneous Manifestations. *Southern Medical Journal.* 2016;109(10):636-46.
3. Dryden M, Baguneid M, Eckmann C, Corman S, Stephens J, Solem C, et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. *Clinical Microbiology and Infection.* 2015;21(s2):S27-S32.
4. Muller SA, Winkelmann RK. Necrobiosis lipoidica diabetorum. A clinical and pathological investigation of 171 cases. *Archives of dermatology.* 1966;93(3):272.
5. O T, Kennedy, Nolan, Young, Rogers, Barnes. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. *British Journal of Dermatology.* 1999;140(2):283-6.
6. Lim C, Tschuchnigg M, Lim J. Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica. *Journal of Cutaneous Pathology.* 2006;33(8):581-3.
7. Boateng B, Hiller D, Albrecht HP, Hornstein OP. Cutaneous microcirculation in pretibial necrobiosis lipoidica. Comparative laser Doppler flowmetry and oxygen partial pressure determinations in patients and healthy probands. *Der Hautarzt.* 1993;44(9):581.
8. Ferringer T, Miller OF. Cutaneous manifestations of diabetes mellitus. *Dermatologic Clinics.* 2002;20(3):483-92.
9. Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: A review of etiology, diagnosis, and treatment options. *Journal of the American Academy of Dermatology.* 2013;69(5):783-91.
10. Paron NG, Lambert PW. CUTANEOUS MANIFESTATIONS OF DIABETES MELLITUS. *Primary Care: Clinics in Office Practice.* 2000;27(2):371-83.
11. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. (Report). 2015;33(1):40.
12. Yamada D, Fujikawa T. Prurigo Pigmentosa. *The American Journal of Medicine.* 2018;131(1):e11-e2.
13. Beutler B, Cohen P, Lee R. Prurigo Pigmentosa: Literature Review. *American Journal of Clinical Dermatology.* 2015;16(6):533-43.
14. Huntley AC. Cutaneous Manifestations of Diabetes Mellitus. *Dermatologic Clinics.* 1989;7(3):531-46.
15. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS, Nagamani M. Acanthosis Nigricans as a Risk Factor for Non-Insulin Dependent Diabetes Mellitus. *Clinical Pediatrics.* 1998;37(2):73-9.
16. Hud JA, Cohen JB, Wagner JM, Cruz PD. Prevalence and significance of acanthosis nigricans in an adult obese population. *Archives of dermatology.* 1992;128(7):941.

p 8-12 Skin Deep cont'd

17. Ponciano DC, Joseph AH. Excess Insulin Binding to Insulin-Like Growth Factor Receptors: Proposed Mechanism for Acanthosis Nigrans. *Journal of Investigative Dermatology*. 1992;98(s6):82S.
18. Sibbald RG, Landolt SJ, Toth D. SKIN AND DIABETES Illustrations for the conditions described in this article can be obtained from the author. *Endocrinology and Metabolism Clinics of North America*. 1996;25(2):463-72.
19. Iversen L, Bygum A. Diabetic dermopathy. *BMJ*. 2018;363.
20. Shemer MA, Bergman MR, Linn MDS, Kantor MY, Friedman-Birnbaum MR. Diabetic dermopathy and internal complications in diabetes mellitus. *International Journal of Dermatology*. 1998;37(2):113-5.
21. Arroyo MP. Generalized granuloma annulare. *Dermatology online journal*. 2003;9(4):13.
22. Sawatkar GU, Kanwar AJ, Dogra S, Bhadada SK, Dayal D. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients. *British Journal of Dermatology*. 2014;171(6):1402-6.
23. Rangunatha S, Anitha B, Inamadar A, Palit A, Devarmani S. Cutaneous disorders in 500 diabetic patients attending diabetic clinic. *Indian Journal of Dermatology*. 2011;56(2):152-6.
24. Studer EM, Calza AM, Saurat JH. Precipitating factors and associated diseases in 84 patients with granuloma annulare: a retrospective study. *Dermatology (Basel, Switzerland)*. 1996;193(4):364.
25. Gange RW, Black MM, Carrington P. Defective neutrophil migration in granuloma annulare, necrobiosis lipoidica, and sarcoidosis. *Archives of dermatology*. 1979;115(1):32.
26. Chen A, Truong AK, Worswick S. The role of biologics in the treatment of chronic granuloma annulare. *International Journal of Dermatology*. 2019;58(5):622-6.
27. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. *Acta dermato-venereologica*. 1987;67(2):175.
28. Cherqaoui R, McKenzie S, Nunlee-Bland G. Diabetic cheiroarthropathy: a case report and review of the literature. *Case Rep Endocrinol*. 2013;2013:257028-.
29. Lister DM, Graham-Brown RA, Burden AC. Resolution of diabetic cheiroarthropathy. *British Medical Journal*. 1986;293(6561):1537.
30. Cole GW, Headley J, Skowsky R. Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus. *Diabetes care*. 1983;6(2):189.
31. Romano G, Moretti G, Di Benedetto A, Giofrè C, Di Cesare E, Russo G, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. *Diabetes Research and Clinical Practice*. 1998;39(2):101-6.
32. Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes mellitus. *Indian Journal of Dermatology, Venereology, and Leprology*. 2003;69(2):105-8.
33. Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Oxford, UK2009. p. 682-94.
34. Le Cleach L, Chosidow O. Lichen Planus. *The New England Journal of Medicine*. 2012;366(8):723-32.
35. Ngo BT, Hayes KD, DiMiao DJ, Srinivasan SK, Huerter CJ, Rendell MS. Manifestations of Cutaneous Diabetic Microangiopathy. *American Journal of Clinical Dermatology*. 2005;6(4):225-37.
36. Farrell AM. Acquiring perforating dermatosis in renal and diabetic patients.(Commentary). *The Lancet*. 1997;349(9056):895.
37. Bologna JL, Jorizzo JL, Schaffer JV. *Dermatology 3rd ed.* [Philadelphia]; London: Elsevier Saunders; 2012.
38. Lynde C, Pratt M. Acquired perforating dermatosis: association with diabetes and renal failure. *Canadian Medical Association Journal*. 2009;181(9):615.
39. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. *Clinical and Experimental Diabetes and Metabolism*. 2008;51(5):747-55.

p 8-12 Skin Deep cont'd

40. Harries RL, Harding KG. Management of Diabetic Foot Ulcers. *Current Geriatrics Reports*. 2015;4(3):265-76.
41. Higa M. Clinical epidemiology of fungal infection in diabetes. *Nihon rinsho Japanese journal of clinical medicine*. 2008;66(12):2239.
42. Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. *Expert Opinion on Drug Safety*. 2010;9(2):225-31.
43. Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard M-A, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. *Journal of the American Academy of Dermatology*. 2018;78(6):1090-6.
44. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. *Journal of the European Academy of Dermatology and Venereology*. 2012;26(2):249-53.
45. Dass AS, Immaculate G, Bhattacharyya A. Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience. *Indian J Endocrinol Metab*. 2019;23(1):165-6.
46. Safety Alerts for Human Medical Products - SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area. *Heart Disease Weekly*. 2018:126.

p 14-16 Diabetes of the exocrine pancreas

1. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. *Diabetes Care*. 2019;42(Suppl 1):S13-S28.
2. Organization GWH. Classification of diabetes mellitus. 2019.
3. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. *Pancreatology*. 2011;11(3):279-94.
4. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). *Diabetes Metab Res Rev*. 2012;28(4):338-42.
5. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease? *Eur J Intern Med*. 2013;24(3):203-6.
6. Malka D, Hammel P, Sauvanet A, Rufat P, O'Toole D, Bardet P, et al. Risk factors for diabetes mellitus in chronic pancreatitis. *Gastroenterology*. 2000;119(5):1324-32.
7. Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. *Pancreatology*. 2013;13(4):336-42.
8. Valenzuela JE, Taylor IL, Walsh JH. Pancreatic polypeptide response in patients with chronic pancreatitis. *Dig Dis Sci*. 1979;24(11):862-4.
9. Andersen DK. Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. *Pancreas*. 2007;35(1):1-15.
10. Cersosimo E, Pistors PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. *Cancer*. 1991;67(2):486-93.
11. Kien CL, Horswill CA, Zipf WB, McCoy KS, O'Dorisio T. Elevated hepatic glucose production in children with cystic fibrosis. *Pediatr Res*. 1995;37(5):600-5.
12. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. *World J Surg*. 2001;25(4):452-60.
13. Andersen BN, Scheel J, Rune SJ, Worning H. Exocrine pancreatic function in patients with dyspepsia. *Hepatogastroenterology*. 1982;29(1):35-7.
14. Domschke S, Stock KP, Pichl J, Schneider MU, Domschke W. Beta-cell reserve capacity in chronic pancreatitis. *Hepatogastroenterology*. 1985;32(1):27-30.
15. American Diabetes A. Classification and diagnosis of diabetes. *Diabetes Care*. 2015;38 Suppl:S8-S16.

p 14-16 Diabetes of the exocrine pancreas cont'd

16. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. *Diabetes Care*. 2010;33(12):2697-708.
17. Petrov MS. Diabetes of the exocrine pancreas: American Diabetes Association-compliant lexicon. *Pancreatology*. 2017;17(4):523-6.
18. Duggan SN, Ewald N, Kelleher L, Griffin O, Gibney J, Conlon KC. The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis. *Eur J Clin Nutr*. 2017;71(1):3-8.
19. Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. *Sci Rep*. 2018;8(1):782.
20. Storgaard H, Cold F, Gluud LL, Vilsboll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. *Diabetes Obes Metab*. 2017;19(6):906-8.
21. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin Therapy to Improve BMI in Cystic Fibrosis-Related Diabetes Without Fasting Hyperglycemia: Results of the Cystic Fibrosis Related Diabetes Therapy Trial. *Diabetes Care*. 2009;32(10):1783-8.
22. Liao K-F, Lai S-W, Li C-I, Chen W-C. Diabetes mellitus correlates with increased risk of pancreatic cancer: A population-based cohort study in Taiwan. *Journal of Gastroenterology and Hepatology*. 2012;27(4):709-13.
23. Wang Z, Lai S-T, Xie L, Zhao J-D, Ma N-Y, Zhu J, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*. 2014;106(1):19-26.
24. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. *Diabetes*. 2013;62(7):2595-604.
25. Chai S, Yu S, Yang Z, Wu S, Gao L, Wang H, et al. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. *BMJ Open Diabetes Res Care*. 2019;7(1):e000728-e.

P18-21 Polypharmacy and deprescribing

When Pollyanna prompts polypharmacy

1. Colley CA, Lucas LM. Polypharmacy - The cure becomes the disease. Vol. 8, *Journal of General Internal Medicine*. 1993. p. 278–83
2. Sirois C, Domingues NS, Laroche M-L, Zongo A, Lunghi C, Guénette L, et al. Polypharmacy Definitions for Multimorbid Older Adults Need Stronger Foundations to Guide Research, Clinical Practice and Public Health. *Pharmacy*. 2019 Aug 29;7(3):126.
6. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: Misleading, but manageable. *Clin Interv Aging*. 2008;3(2):383–9.
7. Hilmer SN. The dilemma of polypharmacy. Vol. 31, *Australian Prescriber*. Australian Government Publishing Service; 2008. p. 2–3.
8. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation: Making it safe and sound [Internet]. [cited 2020 Jan 3]. Available from: www.kingsfund.org.uk
9. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: A real need to deprescribe in older patients. *Med J Aust*. 2014 Oct 6;201(7).

P18-21 Polypharmacy and deprescribing cont'd

Deprescribing hypoglycaemics

1. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing Inappropriate Polypharmacy. *JAMA Intern Med.* 2015;175(5).
2. Tang TS, Funnell MM, Noorulla S, Oh M, Brown MB. Sustaining short-term improvements over the long-term: Results from a 2-year diabetes self-management support (DSMS) intervention. *Diabetes Res Clin Pract.* 2012 Jan;95(1):85–92.
3. Nathan DM, Barrett-Connor E, Crandall JP, Edelstein SL, Goldberg RB, Horton ES, et al. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. *Lancet Diabetes Endocrinol.* 2015 Nov 1;3(11):866–75.
4. Huang XL, Pan JH, Chen D, Chen J, Chen F, Hu TT. Efficacy of lifestyle interventions in patients with type 2 diabetes: A systematic review and meta-analysis. *Eur J Intern Med.* 2016 Jan 1;27:37–47.
5. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: Results from the Diabetes Prevention Program Outcomes Study. *Lancet.* 2012;379(9833):2243–51.
5. Toivo T, Airaksinen M, Dimitrow M, Savela E, Pelkonen K, Kiuru V, et al. Enhanced coordination of care to reduce medication risks in older home care clients in primary care: a randomized controlled trial. *BMC Geriatr.* 2019 Nov 27;19(1):332.
6. Qi K, Reeve E, Hilmer SN, Pearson SA, Matthews S, Gnjidic D. Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. *Int J Clin Pharm.* 2015 Oct 1;37(5):949–57.
7. Reeve E, Low LF, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications: A qualitative focus group study. *Br J Gen Pract.* 2016 Aug 1;66(649):e552–60.
- 8&9 reference numbers not used.
10. Thompson AM, Linnebur SA, Vande Griend JP, Saseen JJ. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult. Vol.
11. Abdelhafiz AH, Sinclair AJ. Management of type 2 diabetes in older people. Vol. 4, *Diabetes Therapy.* Springer Publishing Company; 2013. p. 13–26.
12. Moghissi E. Management of type 2 diabetes mellitus in older patients: Current and emerging treatment options. Vol. 4, *Diabetes Therapy.* Springer Publishing Company; 2013. p. 239–56.
13. Brown A, Mangione C, Saliba D, Sarkisian C. Guidelines for improving the care of the older person with diabetes mellitus. *J Am Geriatr Soc.* 51(5 Suppl Guidelines):S256-80.
14. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. *Lancet.* 2010;375(9713):481–9.
15. Gerstein HC, et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *N Engl J Med* [Internet]. 2008 Jun 12 [cited 2020 Jan 4];358(24):2545–59. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa0802743>
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *N Engl J Med* [Internet]. 2008 Oct 9 [cited 2018 Apr 5];359(15):1577–89. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJMoa0806470>
17. Primary Health Tasmania. *Antihyperglycaemic Agents: A guide to deprescribing.* 2019.

Reducing iatrogenic harm

4. Barnett N, Kelly O. Deprescribing: Is the law on your side? *Eur J Hosp Pharm.* 2017 Jan 1;24(1):21–5.

How to go about deprescribing

1. NHS Scotland. 7 Steps [Internet]. Polypharmacy Guidance- Medicines Review. 2020 [cited 2020 Jan 2]. Available from: <http://www.polypharmacy.scot.nhs.uk/polypharmacy-guidance-medicines-review/for-healthcare-professionals/7-steps/>

P18-21 Polypharmacy and deprescribing cont'd

2. Tenni P, Dunbabin D, Davis J, Lo A, MacKean J, Pollard H, et al. A Guide to Deprescribing: General Information [Internet]. primaryhealthtas.com.au. 2019 [cited 2019 Dec 8]. Available from: <https://www.primaryhealthtas.com.au/wp-content/uploads/2018/09/A-Guide-to-Deprescribing-Anthyperglycaemics-2019.pdf>
3. Kroenke K. Polypharmacy. Causes, consequences, and cure. *The American Journal of Medicine*. 1985;79(2):149–52.
4. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med* [Internet]. 2001 Sep [cited 2020 Jan 3];16(9):606–13. Available from: <http://link.springer.com/10.1046/j.1525-1497.2001.016009606.x>
5. Murray MD, Kroenke K. Polypharmacy and medication adherence: Small steps on a long road. Vol. 16, *Journal of General Internal Medicine*. 2001. p. 137–9.

P22-24 Tai Chi for diabetes

1. Lam P et al. Improving Glycaemic and BP Control in Type 2 Diabetes - the effectiveness of tai chi. *Australia Family Physician* Vol. 37, No. 10, October 2008
2. Sond R et al. Adhering to a T'ai Chi program to improve glucose control and quality of life for individuals with type 2 Diabetes. *Journal Of Alternative And Complementary Medicine*. Vol. 18, No 12, 2012, pp. 1172–1178
3. Ahn S et al. Effects of Tai Chi exercise on glucose control, neuropathy scores, balance, and quality of life in patients with type 2 diabetes and neuropathy. *Journal Of Alternative And Complementary Medicine*. Vol 18, No 12, 2012, pp 1172–1178
4. Zhou Z et al. Effects of Tai Chi on physiology, balance and quality of life in Patients with type 2 diabetes: a systematic review and metaanalysis. *J Rehabil Med* 2019; 51: 405–417
5. Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New England Journal of Medicine*. 3 May 2001
6. Wang F et al. The effects of tai chi on depression, anxiety, and psychological well-being: a systematic review and meta-analysis.

P30-31 Reality Check – Emotional challenge of long-term doctoring

1. Campbell, C. and McGauley, G. (2005). Doctor-patient relationships in chronic illness: insights from forensic psychiatry. *BMJ* 330: 667
2. Braillard, O., Slama-Chaudhry, A., Joly, C., Perone, N., and Beran, D. (2018) The impact of chronic disease management on primary care doctors in Switzerland: a qualitative study, *BMC Family Practice*,19.
3. Oldroyd, J., Proudfoot, J., Infante, F., Powell Davies, G., Harris, M., Bubner, T., Holton, C., and Beilby, J. (2003). Providing healthcare for people with chronic illness: the views of Australian GPs. *Medical Journal of Australia*, 179(1): 30-33

p32 – p34 Food Stuff – Coeliac disease and diabetes: dietary strategies

1. Vajravelu ME et al. Incidence and risk of celiac disease after type 1 diabetes: A population based cohort study using the health improvement network database. *Pediatric Diabetes*. 2018;19:1422–1428
2. Tortora R, et al. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. *Aliment Pharmacol Ther*. 2015 Feb;41(4):352-9.
3. Tovoli F, et al. Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet. *Aliment Pharmacol Ther*. 2018;48(5):538-546.
4. Paterson M et al. The role of dietary protein and fat in glycaemic control in type 1 diabetes: Implications for intensive diabetes management. (2015)*Current diabetes reports*, 15(9), 61.